G1 Therapeutics, Inc.

Symbol: GTHX

NASDAQ

4.98

USD

Market price today

  • -8.4932

    P/E Ratio

  • -0.3788

    PEG Ratio

  • 260.36M

    MRK Cap

  • 0.00%

    DIV Yield

G1 Therapeutics, Inc. (GTHX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.92%

Operating Profit Margin

-0.27%

Net Profit Margin

-0.36%

Return on Assets

-0.30%

Return on Equity

0.19%

Return on Capital Employed

-0.33%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. John E. Bailey Jr.
Full-time employees:100
City:Research Triangle Park
Address:700 Park Offices Drive
IPO:2017-05-17
CIK:0001560241

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

General Outlook

When we look at how much money they make before expenses, they keep 0.919% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.272%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.364%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.300% return, is a testament to G1 Therapeutics, Inc.'s adeptness in optimizing resource deployment. G1 Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.189%. Furthermore, the proficiency of G1 Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.329% return on capital employed.

Stock Prices

G1 Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $4.24, while its low point bottomed out at $3.52. This variance in figures offers investors a lucid insight into the roller-coaster ride that is G1 Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing GTHX liquidity ratios reveals its financial health of the firm. The current ratio of 293.96% gauges short-term asset coverage for liabilities. The quick ratio (235.88%) assesses immediate liquidity, while the cash ratio (61.19%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio293.96%
Quick Ratio235.88%
Cash Ratio61.19%

Profitability Ratios

GTHX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -32.69% underscores its earnings before tax deductions. The effective tax rate stands at -11.34%, revealing its tax efficiency. The net income per EBT, 111.34%, and the EBT per EBIT, 120.36%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -27.16%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-32.69%
Effective Tax Rate-11.34%
Net Income per EBT111.34%
EBT per EBIT120.36%
EBIT per Revenue-27.16%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.94, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 721.13% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding236
Days of Inventory Outstanding672
Operating Cycle722.66
Days of Payables Outstanding274
Cash Conversion Cycle449
Receivables Turnover7.21
Payables Turnover1.33
Inventory Turnover0.54
Fixed Asset Turnover14.04
Asset Turnover0.82

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.35, and free cash flow per share, -0.35, depict cash generation on a per-share basis. The cash per share value, 1.25, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.22, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.35
Free Cash Flow per Share-0.35
Cash per Share1.25
Operating Cash Flow Sales Ratio-0.22
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-0.42
Short Term Coverage Ratio-3.06

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 42.24%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.55, we discern the balance between debt and equity financing. The long-term debt to capitalization, 57.25%, and total debt to capitalization, 60.84%, ratios shed light on its capital structure. An interest coverage of -4.86 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio42.24%
Debt Equity Ratio1.55
Long Term Debt to Capitalization57.25%
Total Debt to Capitalization60.84%
Interest Coverage-4.86
Cash Flow to Debt Ratio-0.42
Company Equity Multiplier3.68

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.59, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.93, reflects the portion of profit attributed to each share. The book value per share, 0.68, represents the net asset value distributed per share, while the tangible book value per share, 0.68, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.59
Net Income Per Share-0.93
Book Value Per Share0.68
Tangible Book Value Per Share0.68
Shareholders Equity Per Share0.68
Interest Debt Per Share1.22

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 60.84%, indicates top-line expansion, while the gross profit growth, 58.38%, reveals profitability trends. EBIT growth, 70.97%, and operating income growth, 70.97%, offer insights into operational profitability progression. The net income growth, 67.49%, showcases bottom-line expansion, and the EPS growth, 72.49%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth60.84%
Gross Profit Growth58.38%
EBIT Growth70.97%
Operating Income Growth70.97%
Net Income Growth67.49%
EPS Growth72.49%
EPS Diluted Growth72.49%
Weighted Average Shares Growth18.58%
Weighted Average Shares Diluted Growth18.58%
Operating Cash Flow Growth70.19%
Free Cash Flow Growth70.31%
10-Year Revenue Growth per Share87.72%
3-Year Revenue Growth per Share33.41%
10-Year Operating CF Growth per Share86.00%
5-Year Operating CF Growth per Share66.77%
3-Year Operating CF Growth per Share66.48%
10-Year Net Income Growth per Share84.15%
5-Year Net Income Growth per Share63.78%
3-Year Net Income Growth per Share64.62%
10-Year Shareholders Equity Growth per Share-75.84%
5-Year Shareholders Equity Growth per Share110.63%
3-Year Shareholders Equity Growth per Share105.94%
Receivables Growth14.36%
Inventory Growth-23.10%
Asset Growth-35.34%
Book Value per Share Growth-56.59%
Debt Growth-31.75%
R&D Expense Growth-47.54%
SGA Expenses Growth-29.16%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 182,679,135.35, captures the company's total value, considering both debt and equity. Income quality, 0.80, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value182,679,135.35
Income Quality0.80
Research and Development to Revenue52.98%
Stock-Based Compensation to Revenue17.59%
Graham Number3.78
Return on Tangible Assets-39.47%
Graham Net Net0.23
Working Capital85,232,000
Tangible Asset Value35,386,000
Net Current Asset Value28,794,000
Invested Capital1
Average Receivables11,890,500
Average Payables5,711,500
Average Inventory14,310,500
Days Sales Outstanding56
Days Payables Outstanding203
Days of Inventory On Hand631
ROIC-47.92%
ROE-1.36%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 9.37, and the price to book ratio, 9.37, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.10, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -14.32, and price to operating cash flows, -14.29, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio9.37
Price to Book Ratio9.37
Price to Sales Ratio3.10
Price Cash Flow Ratio-14.29
Price Earnings to Growth Ratio-0.38
Enterprise Value Multiple-10.98
Price Fair Value9.37
Price to Operating Cash Flow Ratio-14.29
Price to Free Cash Flows Ratio-14.32
Price to Tangible Book Ratio4.46
Enterprise Value to Sales2.21
Enterprise Value Over EBITDA-4.68
EV to Operating Cash Flow-4.77
Earnings Yield-30.40%
Free Cash Flow Yield-24.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of G1 Therapeutics, Inc. (GTHX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -8.493 in 2024.

What is the ticker symbol of G1 Therapeutics, Inc. stock?

The ticker symbol of G1 Therapeutics, Inc. stock is GTHX.

What is company IPO date?

IPO date of G1 Therapeutics, Inc. is 2017-05-17.

What is company current share price?

Current share price is 4.980 USD.

What is stock market cap today?

The market cap of stock today is 260361372.000.

What is PEG ratio in 2024?

The current -0.379 is -0.379 in 2024.

What is the number of employees in 2024?

In 2024 the company has 100.